Lysosomal Diseases and Neuropsychiatry: Opportunities to Rebalance the Mind.

The brain is the physical organ of the mind but efforts to understand mental illness within a neurobiological context have hitherto been unavailing. Mental disorders (anxiety, depression, bipolar disorder, and schizophrenia) affect about one fifth of the population and present an almost endless societal challenge at the frontier of human sciences. Prodigious technological advances in functional neuroimaging and large-scale genetics have not yet delivered the prospect of refined molecular understanding of mental illness beyond early anatomical descriptions of brain metabolism. However, intensive clinical phenotyping and quantitative metabolic studies using sophisticated radio-ligands in positron-emission tomography, persistently favor the neurobiological approach. This Perspective pursues a familiar maxim in Medicine, aptly summarized in the words of Arthur Koestler: "Nature is generous in her senseless experiments on mankind." Hitherto, studies in neuropsychiatry have largely ignored rare genetic disorders but derangements of specific components within the cerebral laboratory offer rich opportunities for mechanistic exploration. Aberrant psychic behavior is characteristic of many inborn errors of metabolism and although each disorder represents a universe of its own, we are at a threshold for understanding, since contemporary genetics and cell biology furnish abundant materials to take on the perturbing enigma of mental derangement. A further development relates to orphan drugs with actions on defined molecular targets: these represent new ways to study the pathogenesis of psychiatric phenomena associated with rare diseases and in a manner not formerly possible. Here we introduce the frontier of schizophrenia and its strong association with late-onset Tay-Sachs disease as a paradigm to explore

Imiglucerase in the treatment of Gaucher disease: a history and perspective

The scientific and therapeutic development of imiglucerase (Cerezyme®) by the Genzyme Corporation is a paradigm case for a critical examination of current trends in biotechnology. In this article the authors argue that contemporary interest in treatments for rare diseases by major pharmaceutical companies stems in large part from an exception among rarities: the astonishing commercial success of Cerezyme. The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease

Stability and Controls Analysis and Flight Test Results of a 24-Foot Telescoping Nose Boom on an F-15B Airplane

The Quiet Spike(TradeMark) F-15B flight research program investigated supersonic shock reduction using a 24-ft telescoping nose boom on an F-15B airplane. The program goal was to collect flight data for model validation up to 1.8 Mach. In the area of stability and controls, the primary concerns were to assess the potential destabilizing effect of the oversized nose boom on the stability, controllability, and handling qualities of the airplane and to ensure adequate stability margins across the entire research flight envelope. This paper reports on the stability and control analytical methods, flight envelope clearance approach, and flight test results of the F-15B telescoping nose boom configuration. Also discussed are brief pilot commentary on typical piloting tasks and refueling tasks

MID1 and MID2 homo- and heterodimerise to tether the rapamycin-sensitive PP2A regulatory subunit, Alpha 4, to microtubules: implications for the clinical variability of X-linked Opitz GBBB syndrome and other developmental disorders

BACKGROUND: Patients with Opitz GBBB syndrome present with a variable array of developmental defects including craniofacial, cardiac, and genital anomalies. Mutations in the X-linked MID1 gene, which encodes a microtubule-binding protein, have been found in ~50% of Opitz GBBB syndrome patients consistent with the genetically heterogeneous nature of the disorder. A protein highly related to MID1, called MID2, has also been described that similarly associates with microtubules. RESULTS: To identify protein partners of MID1 and MID2 we undertook two separate yeast two-hybrid screens. Using this system we identified Alpha 4, a regulatory subunit of PP2-type phosphatases and a key component of the rapamycin-sensitive signaling pathway, as a strong interactor of both proteins. Analysis of domain-specific deletions has shown that the B-boxes of both MID1 and MID2 mediate the interaction with Alpha 4, the first demonstration in an RBCC protein of a specific role for the B-box region. In addition, we show that the MID1/2 coiled-coil motifs mediate both homo- and hetero-dimerisation, and that dimerisation is a prerequisite for association of the MID-Alpha 4 complex with microtubules. CONCLUSIONS: Our findings not only implicate Alpha 4 in the pathogenesis of Opitz GBBB syndrome but also support our earlier hypothesis that MID2 is a modifier of the X-linked phenotype. Of further note is the observation that Alpha 4 maps to Xq13 within the region showing linkage to FG (Opitz-Kaveggia) syndrome. Overlap in the clinical features of FG and Opitz GBBB syndromes warrants investigation of Alpha 4 as a candidate for causing FG syndrome

Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections

Background: Plasmodium knowlesi is a cause of symptomatic and potentially fatal infections in humans. There are no studies assessing the detailed parasitological response to treatment of knowlesi malaria infections in man and whether antimalarial resistance occurs. Methods: A prospective observational study of oral chloroquine and primaquine therapy was conducted in consecutive patients admitted to Kapit Hospital, Sarawak, Malaysian Borneo with PCR-confirmed single P. knowlesi infections. These patients were given oral chloroquine for three days, and at 24 hours oral primaquine was administered for two consecutive days, primarily as a gametocidal agent. Clinical and parasitological responses were recorded at 6-hourly intervals during the first 24 hours, daily until discharge and then weekly to day 28. Vivax malaria patients were studied as a comparator group. Results: Of 96 knowlesi malaria patients who met the study criteria, 73 were recruited to an assessment of the acute response to treatment and 60 completed follow-up over 28 days. On admission, the mean parasite stage distributions were 49.5%, 41.5%, 4.0% and 5.6% for early trophozoites, late trophozoites, schizonts and gametocytes respectively. The median fever clearance time was 26.5 [inter-quartile range 16-34] hours. The mean times to 50% (PCT50) and 90% (PCT90) parasite clearance were 3.1 (95% confidence intervals [CI] 2.8-3.4) hours and 10.3 (9.4-11.4) hours. These were more rapid than in a group of 23 patients with vivax malaria 6.3 (5.3-7.8) hours and 20.9 (17.6-25.9) hours; P = 0.02). It was difficult to assess the effect of primaquine on P. knowlesi parasites, due to the rapid anti-malarial properties of chloroquine and since primaquine was administered 24 hours after chloroquine. No P. knowlesi recrudescences or re-infections were detected by PCR. Conclusions: Chloroquine plus primaqine is an inexpensive and highly effective treatment for uncomplicated knowlesi malaria infections in humans and there is no evidence of drug resistance. Further studies using alternative anti-malarial drugs, including artemisinin derivatives, would be desirable to define optimal management strategies for P. knowlesi.Publisher PDFPeer reviewe

Alternative models of instant drug testing: evidence from an experimental trial

Objective This study describes and provides relapse and recidivism outcome findings related to an experimental trial evaluating the viability of frequent, random drug testing with consequences for use. Methods The sample consisted of 529 offenders released on parole. An experimental design with random assignment to one of three groups was employed. The Experimental Group received frequent, random drug testing with instant results, immediate sanctions, and referral for substance abuse treatment. Control Group I received frequent, random drug testing and treatment referral, but did not receive immediate test results or immediate sanctions. Control Group II followed standard parole practice. Members of this group were not tested on a random basis and did not receive immediate sanctions. Repeated measures ANOVA and survival analysis techniques were used to explore group differences. Results Frequent monitoring of drug use with randomized testing protocols, immediate feedback, and certain consequences is effective in lowering rates of relapse and recidivism. The effectiveness is particularly salient in the short term during the period of exposure to testing conditions. Conclusions The findings lend support to the use of randomized testing with swift and certain sanctions with parolees. Additional quality evidence is necessary to generalize and refine findings from this study and others that focus on sanction certainty. Future replications must consider the immediacy of test result and sanction execution as well as the length of exposure to randomized testing periods

EVOLVE Mentor Program

This is a presentation of the EVOLVE mentor program at the Indiana Department of Transportation which shows a model of linking talent strategy to business strategy. This started as a pilot program for Engineers-in-Training who expressed a desire for mentorship and career guidance. The program included 1:1 mentor/mentee pairings as well as group mentoring

Roscoe O. Brady: Physician whose pioneering discoveries in lipid biochemistry revolutionized treatment and understanding of lysosomal diseases.

Medical Biochemistr

Long-Term High-Temperature Stability of Functionalized Graphene Oxide Nanoplatelets in Arab-D and API Brine

Partially reduced graphene oxide (prGO) was covalently functionalized with a zwitterionic polymer polyzwitterionic polymer to afford a composite material with excellent dispersibility and long-term stability in high salinity brines including standard API and Arab-D found in deep oil reservoirs. When heated at 90 °C, the dispersions remained stable in excess of 140 days. These results suggest the utility of imidazolium-based polymers for brine stabilization as well as the use of diazonium containing polymers for a “grafting-to” approach to nanocarbon functionalization.Saudi Aramco (MIT Energy Initiative)Massachusetts Institute of Technology. Institute for Soldier NanotechnologiesCamille & Henry Dreyfus Foundation. Postdoctoral Program in Environmental Chemistry (Fellowship